Jean Klášterský - Concepedia

Author

Jean Klášterský

Also Known As

E A Robinson, J KLASTERSKY, J Klastersky, J. A. Klastersky, J. KLASTERSKY, J. Klastersky, J. Klastérsky, J.A. Klastersky, JEAN KLASTERSKY, Jean A Klastersky

746

Publications

17.7K

Citations

H-Index

174

Concepts

All Affiliations

Institut Jules Bordet Université Libre de Bruxelles UCLouvain

About

Jean Klášterský is an author at Institut Jules Bordet specializing in medicine, clinical microbiology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	32	76	3.3K
2	Arts	3	3	129
3	Education	1	1	68
4	Engineering	1	1	32
5	Management	1	1	21

Jean Klášterský

219

Publications

13.6K

Citations

H-Index

Page 1

	Year	Citations
The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients Jean Klášterský, Marianne Paesmans, Edward Rubenstein, Journal of Clinical Oncology	2000	1.1K
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines Jean Klášterský, Julien de Naurois, K. V. I. Rolston, Annals of Oncology Febrile NeutropaeniaClinical Case ReportClinical ReviewClinical EpidemiologyMedicine	2016	720
Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. The EORTC international antimicrobial therapy project group. Schimpff Sc, H. Gaya, Jean Klášterský, PubMed OncologyFebrile Granulocytopenic PatientsAntimicrobial StewardshipAntibioticsAntibiotic Regimens	1978	457
Oral versus Intravenous Empirical Antimicrobial Therapy for Fever in Patients with Granulocytopenia Who Are Receiving Cancer Chemotherapy Winfried V. Kern, Alain Cometta, R. De Bock, New England Journal of Medicine	1999	373
Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients Olle Ringdén, F. Meunier, J Tollemar, Journal of Antimicrobial Chemotherapy	1991	281
Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program Alain Cometta, Thierry Calandra, H. Gaya, Antimicrobial Agents and Chemotherapy Empiric TherapyAntibioticsAntimicrobial StewardshipMedicineGranulocytopenic Patients	1996	275
Management of Fever in Neutropenic Patients with Different Risks of Complications Jean Klášterský Clinical Infectious Diseases	2004	273
A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. Jean Klášterský, Jean‐Paul Sculier, H. Lacroix, Journal of Clinical Oncology Advanced NsclcMedicineCancer ManagementMetronomic TherapyPharmacology	1990	246
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer Alain Cometta, Stephen H. Zinner, R. De Bock, Antimicrobial Agents and Chemotherapy PathologyAmikacin Versus CeftazidimePharmacotherapyAntimicrobial ChemotherapyDrug Resistance	1995	246
Antibacterial Activity in Serum and Urine as a Therapeutic Guide in Bacterial Infections Jean Klášterský, D. Daneau, G. Swings, The Journal of Infectious Diseases Trough LevelsAntibiotic AdjuvantAntibacterial ActivityTherapeutic GuideAntimicrobial Chemotherapy	1974	237

Page 1